Partner

Articles & Insights / Natural Products

Botanical Extract Standardisation Beyond a Marker Assay

Botanical quality depends on identity, composition, processing and contaminant control. A marker result is useful only when it sits within a broader system that describes what the extract is and how consistently it can be produced.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Establish the identity of the starting material
  • Describe the extract precisely
  • Choose markers for a defined purpose

Establish the identity of the starting material

Document the botanical name, plant part, geographical origin and relevant collection or cultivation information. Different species or plant parts can produce extracts with different compositions. Authentication may combine botanical examination, microscopy, chemical profiling and other appropriate techniques. No single tool is universally sufficient for every material.

DNA-based methods can help answer some identity questions, but processing may degrade DNA and mixed products create interpretation challenges. Chemical identity tests should address the actual extract matrix rather than rely exclusively on a raw-plant method. WHO’s herbal-material quality guidance provides a basis for selecting suitable material tests. R22

Describe the extract precisely

Record extraction solvent, process conditions, yield, concentration and drying approach. Distinguish the native extract from added carriers or processing aids. A drug-extract ratio must be interpreted with its stated basis; a large ratio does not automatically establish higher potency or clinical superiority.

For example, two extracts can deliver the same marker percentage while differing in solvent history, carrier content and the broader constituent profile. A procurement specification that records only the marker may allow substantial changes that affect stability, taste or performance. The illustration shows the evidence layers needed to characterise the material.

Explore the scienceNatural Products

Layers of botanical evidence

IdentityExtract definitionChemical fingerprintQuality controls
Botanical identity

Establish species, plant part and traceable source information.

Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.

Identity, extract definition, chemical characterisation and quality controls provide complementary information. A marker assay alone cannot establish all four layers.

Choose markers for a defined purpose

A marker may be associated with biological activity, used for analytical consistency or selected because it helps identify the material. State its role. Where a marker is not established as the relevant active constituent, its assay should not be presented as a direct measure of clinical efficacy.

Use appropriately characterised reference materials and assess extraction recovery. Botanical matrices can interfere with chromatographic or spectroscopic methods. A clean-looking peak does not establish the absence of co-elution, and one successful method may not detect substitution or selective addition of a marker compound.

Add a meaningful chemical fingerprint

A fingerprint examines a broader pattern of constituents. Select the technique and comparison rules to distinguish expected variability from a potentially significant change. Define which peaks or regions are important and how normalisation or alignment is handled. A mathematical similarity score should be linked to chemically meaningful features.

The ConPhyMP research guidelines emphasise transparent characterisation of extracts used in pharmacological and toxicological studies. Their relevance here is traceability between a tested extract and the material being described. They are research reporting guidance, not a substitute for the regulatory specification of a commercial botanical product. R23

Control contaminants and processing residues

Assess relevant pesticides, elemental contaminants, microbial quality, mycotoxins, residual solvents and adulterants using the applicable product requirements. The risk profile depends on origin, cultivation, processing and intended use. A supplier qualification programme should address authenticity and variability as well as the latest certificate of analysis.

Sampling is particularly important for heterogeneous materials. A small, poorly representative sample can miss localised contamination or material substitution. Define how incoming material is sampled and retained, and ensure that the method’s reporting limit is suitable for the specification.

Connect standardisation to stability and evidence

During stability studies, consider marker content, fingerprint, physical properties and relevant contaminants or degradation products. Browning, precipitation or odour change may be informative even when a marker remains acceptable. Investigate whether the change reflects chemistry, moisture, processing or packaging interaction.

Clinical or pharmacological findings apply to the material and conditions studied. Transferring them to another extract requires a justified comparison of composition, dose and other relevant attributes. FDA’s botanical-drug guidance concerns medicines developed through its drug pathways; it does not automatically apply to all botanical supplements. R27

Stabicon can support botanical characterisation and analytical development so that identity, consistency and stability are addressed in one coherent programme. The result is a more useful specification for development, procurement and evidence generation.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R22
    WHO Quality Control Methods for Herbal Materials

    WHO publication, 2011. Material identity and quality-testing framework.

  2. R23
    Heinrich and colleagues ConPhyMP Guidelines

    Frontiers in Pharmacology, 2022, volume 13, article 953205. Research characterisation and reporting guidance.

  3. R27
    FDA Botanical Drug Development

    Final guidance, December 2016. Botanical medicines under drug-development pathways; not all botanical supplements.

  4. R21
    FSSAI Health Supplements and Nutraceuticals Standards

    Official regulations portal. Verify current amendments, permitted ingredients, levels and category-specific requirements.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin